--- name: managing-gynecologic-screening language: en description: Applies ASCCP cervical cancer screening guidelines with HPV co-testing and colposcopy indications. Use when managing cervical screening, applying ASCCP guidelines, or determining colposcopy need. tags: - management - obstetrics-and-gynecology metadata: author: casemark practice_areas: - Obstetrics - Gynecology - Maternal-Fetal Medicine document_types: - Management Report skill_modes: - Management - Coordination --- # Managing Gynecologic Screening Applies ASCCP risk-based cervical cancer screening guidelines, Bethesda System cytology classification, HPV co-testing protocols, and colposcopy indications for evidence-based cervical cancer prevention. ## Why This Skill Exists Cervical cancer is a largely preventable disease through screening and HPV vaccination. The 2019 ASCCP Risk-Based Management Consensus Guidelines replaced the prior algorithm-based approach with a risk-estimation framework where management is determined by the patient's estimated risk of CIN 3+ rather than by individual test results alone. The Bethesda System for Reporting Cervical Cytology provides the standardized terminology (ASC-US, LSIL, HSIL, AGC, etc.) that clinicians must use when documenting results. Errors in screening management — over-screening low-risk patients, under-screening high-risk patients, or failing to refer for colposcopy when indicated — contribute to both unnecessary procedures and missed cancers. This skill ensures that every screening decision follows the ASCCP risk thresholds and is properly documented. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. **Patient age** — screening recommendations vary by age group. (Default: from demographics) 2. **HPV vaccination status** — vaccinated patients still require screening per guidelines. (Default: from immunization record) 3. **Screening history** — last Pap/HPV test date and results? Any prior abnormal results? (Default: from prior lab reports) 4. **HIV status** — HIV-positive patients have separate screening intervals. (Default: from chart) 5. **Immunosuppression status** — organ transplant, chronic steroid use, other immunosuppression? (Default: from problem list) 6. **Prior treatment history** — LEEP, cone biopsy, cryotherapy, or hysterectomy? (Default: from surgical history) 7. **Pregnancy status** — Pap screening may be performed but colposcopy management differs in pregnancy. (Default: confirm) 8. **DES exposure** — in utero DES exposure requires specialized screening. (Default: ask if age-appropriate) ### Documents to Request - Prior Pap smear results with Bethesda classification - HPV testing results (genotyping: HPV 16/18 vs. other high-risk types) - Colposcopy reports and biopsy pathology - Prior LEEP/cone operative and pathology reports - HIV test results - Immunization records (HPV vaccine series) --- ## Step 1: Apply Age-Based Screening Intervals Per USPSTF/ACOG/ACS/ASCCP recommendations: | Age Group | Screening Recommendation | |---|---| | < 21 years | No screening regardless of sexual history or HPV vaccination | | 21–24 years | Cytology alone every 3 years; NO HPV co-testing | | 25–29 years | Cytology every 3 years, OR HPV primary screening every 5 years (per ACS 2020 update) | | 30–65 years | Cytology + HPV co-testing every 5 years (preferred), OR cytology alone every 3 years, OR HPV primary screening every 5 years | | > 65 years | Discontinue if adequate prior screening (3 consecutive negative cytology or 2 consecutive negative co-tests in prior 10 years, most recent within 5 years) and no history of CIN 2+ in prior 25 years | | Post-hysterectomy (with cervix removed) | Discontinue if no history of CIN 2+ and cervix fully removed | **Special populations:** - **HIV-positive:** Begin screening at age 21, cytology annually; co-testing every 3 years if age ≥ 30 with normal results × 3 - **Immunosuppressed (non-HIV):** Screen per HIV guidelines - **In utero DES exposure:** Annual cytology starting at age of diagnosis --- ## Step 2: Interpret Results Using the Bethesda System ### Cytology Categories (Bethesda 2014) | Bethesda Category | Meaning | Clinical Significance | |---|---|---| | NILM | Negative for intraepithelial lesion or malignancy | Normal result | | ASC-US | Atypical squamous cells of undetermined significance | Mildly abnormal; reflex HPV testing indicated | | ASC-H | Atypical squamous cells, cannot exclude HSIL | Higher concern; colposcopy recommended | | LSIL | Low-grade squamous intraepithelial lesion | Corresponds to HPV effect / CIN 1 | | HSIL | High-grade squamous intraepithelial lesion | Corresponds to CIN 2/3; colposcopy required | | AGC | Atypical glandular cells | Requires colposcopy + endocervical curettage ± endometrial biopsy | | AIS | Adenocarcinoma in situ | Requires colposcopy, ECC, and excisional procedure | | SCC | Squamous cell carcinoma | Invasive cancer — urgent gynecologic oncology referral | ### HPV Results - **HPV negative** — low risk, return to routine screening - **HPV positive (other high-risk, non-16/18)** — risk depends on cytology - **HPV 16 positive** — highest risk; colposcopy regardless of cytology - **HPV 18 positive** — high risk; colposcopy regardless of cytology --- ## Step 3: Apply the 2019 ASCCP Risk-Based Framework Management is based on the **estimated CIN 3+ risk** using current and prior test results: | Estimated CIN 3+ Risk | Recommended Action | |---|---| | < 0.15% | Return to routine 5-year screening | | 0.15–0.54% | Return in 3 years for repeat testing | | 0.55–3.9% | Return in 1 year for repeat testing | | 4.0–24% | Colposcopy recommended | | 25–59% | Colposcopy with biopsy; treatment acceptable | | 60–100% | Excisional treatment recommended (LEEP or cold knife cone) | **Key clinical action thresholds:** - **ASC-US / HPV negative:** Return in 3 years (low risk) - **ASC-US / HPV positive (non-16/18):** Return in 1 year - **ASC-US / HPV 16 or 18 positive:** Colposcopy - **LSIL / HPV negative (ages 25+):** Return in 1 year - **LSIL / HPV positive:** Colposcopy - **HSIL (any HPV result):** Colposcopy; expedited treatment (LEEP) acceptable if not pregnant - **AGC:** Colposcopy + ECC + endometrial biopsy (if age ≥ 35 or risk factors for endometrial cancer) --- ## Step 4: Colposcopy Documentation Requirements When colposcopy is performed, document: 1. **Indication** — cytology result, HPV status, ASCCP risk estimate 2. **Adequacy** — visualization of entire squamocolumnar junction (SCJ) — adequate vs. inadequate 3. **Findings** — acetowhite epithelium, punctation, mosaicism, atypical vessels, lesion size and location (clock positions) 4. **Biopsy location(s)** — number and clock positions of biopsies taken 5. **Endocervical curettage (ECC)** — performed or not, indication 6. **Impression** — low-grade vs. high-grade colposcopic impression 7. **Pathology results** — CIN 1, CIN 2, CIN 3, AIS, invasive carcinoma 8. **Management plan** — surveillance vs. excision based on pathology and ASCCP guidelines --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. **Is the screening interval appropriate** for the patient's age and risk profile? 2. **Are all test results documented** with Bethesda terminology for cytology and specific HPV genotype data? 3. **Does the management plan match** the ASCCP risk-based recommendation for the test result combination? 4. **Is the colposcopy referral documented** when indicated, or is the surveillance plan clearly stated? 5. **Are special populations flagged** — HIV, immunosuppressed, post-treatment, DES exposure? --- ## Quality Audit - [ ] Patient age documented and screening interval matches age-based recommendation - [ ] Cytology result documented using Bethesda System terminology - [ ] HPV result documented with genotype specificity (16, 18, other high-risk, negative) - [ ] ASCCP risk estimate or risk category is stated - [ ] Colposcopy referral documented when CIN 3+ risk ≥ 4% - [ ] Colposcopy adequacy (SCJ visualization) documented when performed - [ ] Biopsy results documented with CIN grade - [ ] ECC performed and results documented for AGC or unsatisfactory colposcopy - [ ] Prior abnormal results are referenced when estimating current risk - [ ] Treatment plan (surveillance vs. excision) is stated with next follow-up date - [ ] HIV and immunosuppression screening protocols applied when applicable - [ ] Post-treatment surveillance documented (at 6 months, 12 months, then annually × 3 years, then every 3 years × 25 years) - [ ] HPV vaccination status documented and vaccine offered if eligible (up to age 45) --- ## Guidelines 1. **Use Bethesda terminology exclusively** — never write "Class II" or "mild dysplasia" in place of the standardized Bethesda terms. 2. **Always pair cytology with HPV result** — isolated cytology interpretation without HPV context leads to incorrect risk estimation. 3. **Do not over-screen** — annual Pap smears are not recommended for average-risk patients over age 30 with negative co-testing; the interval is 5 years. 4. **Age 21–24 is a special group** — LSIL and ASC-US in this age group are managed conservatively due to high regression rates. Do NOT perform HPV co-testing. 5. **AGC triggers a broader workup** — always include ECC and consider endometrial biopsy, especially in patients ≥ 35 or with abnormal bleeding. 6. **Post-treatment surveillance is 25 years** — patients with treated CIN 2+ remain at elevated risk for at least 25 years and must not return to standard population-based screening intervals. 7. **Document the "adequate negative prior" determination** when discontinuing screening at age 65 — list the specific tests and dates that meet exit criteria.